DocumentRX-7518
Issued
Read2 min

FDA Accepts Second Evotec–BMS Molecular Glue IND; Shares Up 2%

FDA accepted Evotec and Bristol Myers Squibb's second molecular glue IND, a CELMoD set for Phase 1 in 2027. First candidate began Phase 1 in March 2026 for advanced clear cell renal cell carcinoma.

TAG T-6577 · 487 words on the filing

Evotec and Bristol Myers Squibb: Second Molecular Glue Drug Candidate's IND Accepted by FDA, Shares Rise 2% Intraday - f
Evotec and Bristol Myers Squibb: Second Molecular Glue Drug Candidate's IND Accepted by FDA, Shares Rise 2% Intraday - fDarkoStojanovic / pixabay

Summary of findings

  • FDA accepted the IND for the second Evotec–BMS molecular glue candidate, a CELMoD, with Phase 1 planned for 2027
  • First collaboration candidate entered Phase 1 in March 2026 for advanced clear cell renal cell carcinoma
  • Evotec shares rose about 2% intraday on the announcement
  • Collaboration began with Celgene in 2018 and expanded in 2022 under Bristol Myers Squibb
  • Evotec holds 100+ proprietary R&D assets and partners with the top 20 pharma companies and 800+ biotechs

Evotec SE said Thursday the FDA accepted the IND for the second drug candidate from its protein degradation collaboration with Bristol Myers Squibb. Evotec's U.S.-listed shares rose roughly 2% intraday on the news.

The candidate is a cereblon E3 ligase modulator, or CELMoD. Evotec plans to start Phase 1 trials in 2027. The indication was not disclosed. The partnership's first candidate, also a molecular glue degrader, entered Phase 1 in March 2026 for advanced clear cell renal cell carcinoma.

How did the collaboration take shape?

The alliance dates to 2018, when Evotec signed a long-term R&D agreement with Celgene. Bristol Myers Squibb later acquired Celgene and expanded the deal's scope in 2022. Evotec supplies industrial-scale multi-omics screening, AI-assisted data analysis and drug design. Bristol Myers Squibb contributes its CELMoD compound library. Together they advance a molecular glue pipeline against high-value oncology targets.

Evotec Chief Scientific Officer Joanna Holbrook said: "The successful advancement of our second molecular glue candidate to IND acceptance fully demonstrates the reproducibility and efficiency of our discovery platform." She added that the achievement underlines the value of the long-term partnership and confidence that the platform can continuously produce clinical-stage candidates.

Why does molecular glue matter?

CELMoDs recruit E3 ubiquitin ligases to target proteins, tagging them for degradation rather than blocking their activity. Traditional small molecules work only as agonists or antagonists and must bind continuously, which leaves roughly 90% of proteins classed as undruggable and often forces daily dosing. CELMoDs induce a new interaction mode between cereblon and substrate proteins, expanding the pharmacologically addressable proteome.

Evotec runs the discovery engine on two internal platforms: PanOmics for high-throughput proteomics and transcriptomics screening, and PanHunter for integrating cellular biology data to prioritize candidates for lead optimization.

What does it signal for the pipeline?

The second IND validates reproducibility, not just luck. One clinical candidate can be a one-off; two successive FDA clearances from the same framework suggest the platform can produce candidates at scale — the condition pharma majors pay milestone money for. But revenue remains distant: IND acceptance only permits human trials, Phase 1 through approval each carry failure risk, and a 2027 trial start means no near-term clinical data. The modest 2% intraday gain reflects that caution.

A third accepted compound would shift Evotec's role from technology service provider toward co-development partner, with consequences for its milestone revenue structure and bargaining power.

Where does Evotec stand overall?

The company holds more than 100 proprietary R&D assets, most co-owned, spanning oncology, cardiovascular and metabolic disease, neuroscience and immunology. It employs roughly 4,500 people across Europe and the United States. Its partners include all of the world's top 20 pharmaceutical companies and more than 800 biotechs.

The takeaway: two IND clearances in two years prove the platform's output; the market still wants clinical data.

via FDA industry wire (Google News) (Source)

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.

11 articles

Linked filings

  1. E-6328
  2. C-4460
  3. K-8919
  4. E-6700
  5. K-8037

« Previous filingNext filing »